Author

Nancy Wyant

Institution: Idera Pharmaceuticals (United States)

Observed institution: Idera Pharmaceuticals (United States)

OpenAlex ID: A5082363078

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

2015 · Sheeba K. Thomas, Wael A. Harb, et al. · Blood · 11

Works count: 1

Citation count: 11

H-index: 1

I10-index: 1